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Background 
Evidence-based risk factors associated with 
Clostridium difficile infectious diarrhea have been 
identified through systematic review of the 
literature.  Factors identified include increasing 
age, increased severity of underlying diseases, 
non-surgical gastrointestinal procedures, presence 
of a nasogastric tube, stays in intensive care units, 
increasing duration of hospital stay, increased 
duration of antibiotic treatment, and multiple 
antibiotic administration.1 
C. difficile is associated with significant 
morbidity, mortality, increased length of hospital 
stay, and increased cost.  Its incidence doubled 
between 2000 and 2002.2  Two recent studies have 
identified the use of proton pump inhibitors as an 
associated risk factor for C. difficile diarrhea.3,4  
Commonly prescribed proton pump inhibitors 
include esomeprazole (Nexium), lansoprazole 
(Prevacid), omeprazole (Prilosec), pantoprazole 
(Protonix), and rabeprazole (Aciphex). 
In the current investigation both cohort and 
case-controlled studies were undertaken to assess 
acid-suppressive therapy as a risk factor for C. 
difficile infection.4  
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Methods 
In the cohort study, 1,187 inpatients who had 
received antibiotics over a nine month period 
were identified.  Patients in this group were 
categorized as to whether they received acid 
suppressive therapy.  They were further 
subdivided by their receipt of either proton pump 
inhibitor or H2-blocker therapy.  Hospital 
laboratory reports were used to confirm positive 
assay results for C. difficile toxin.   
The case-control study was performed to 
address the possibility that patients receiving 
proton pump inhibitors were sicker and had other 
risk factors for C. difficile.  Cases were defined as 
patients with an inpatient history of diarrhea and 
positive assay results for C. difficile toxin.  
Controls were defined as any inpatient within the 
same study time period who received any 
antibiotic and had at least a five-day length of stay 
with survival at least 30 days past admission.  
Controls were also matched to cases by ward, age, 
class of antibiotic, and number of antibiotics.   
The study end point was to determine the risk of 
C. difficile diarrhea in patients receiving proton 
pump inhibitors. 
 
Results 
C. difficile diarrhea developed in 6.8% of the 
cohort patients.  Of the patients who received 
antibiotics and a proton pump inhibitor 9.3% 
developed C. difficile diarrhea.  Whereas those 
who received antibiotics but no proton pump 
inhibitor experienced a 4.4% incidence (RR 2.1, 
95% CI 1.4 to 3.4).  The relative risk of C. 
difficile was higher in patients receiving proton 
pump inhibitors compared with H2-blocker 
recipients (OR 2.1, 95% CI 1.2 to 3.5 vs. OR 1.1, 
95% CI 0.4 to 3.4).   
In the case-control study, 94 patients 
developed C. difficile diarrhea.  The case and 
control subjects were similar in age, number and 
type of antibiotic, and comorbidity factors.  Case 
subjects were more likely to be female, have renal 
disease, MRSA colonization, and had past 
admissions.  It was also noted that one patient 
receiving a proton pump inhibitor but no 
antibiotics, developed C. difficile diarrhea.  Of the 
cases, 64% were receiving proton pump inhibitors 
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Author Conclusions 
Inpatients receiving proton pump inhibitors 
were at greater risk for C. difficile diarrhea. 
 
Commentary 
Clostridium difficile is an anaerobic gram-
positive rod accounting for approximately 15% to 
25% of all causes of antibiotic-associated 
diarrhea.  Some of the clinical signs of infection 
include watery diarrhea, fever, abdominal pain 
and tenderness, and nausea.  It may also cause 
pseudomembranous colitis.5   
It is most frequently transmitted by the hands 
of health care workers who have had contact with 
contaminated feces or environmental surfaces.5 
Symptomatic patients should be tested for C. 
difficile if they are or have recently been 
hospitalized and have taken antibiotics or are 
receiving antibiotics at home or in a nursing care 
facility.  Stool culture and toxin assays are 
recommended diagnostic tests for C. difficile.5 
When C. difficile is confirmed, first-line 
antibiotic treatment with oral metronidazole 
should be prescribed.  The recommended dose is 
250 mg four times daily or 500 mg twice daily for 
ten to 14 days.6  Intravenous metronidazole may 
be effective in those unable to take the drug 
orally.7  Oral vancomycin (125 mg four times 
daily for ten to 14 days) should be reserved for 
those who have failed first-line treatment, are 
intolerant to metronidazole, or have metronidazole 
contraindications. Intravenous vancomycin is not 
excreted into the colon and therefore should not 
be used for C. difficile.6 
Patients who have C. difficile colonization test 
positive but are asymptomatic.  These colonized 
cases should not be treated with antibiotics since 
there is decreased risk for active disease.5  
Prevention and control of C. difficile requires 
contact precautions for all symptomatic cases 
including frequent handwashing, use of gloves, 
use of gowns if soiling is possible, and private 
room placement.  Appropriate medical device and 
environmental cleaning with EPA-approved 
disinfectants is essential.6 
Judicious use of antibiotics is a key 
preventative measure.  The antibiotics most often 
associated with C. difficile diarrhea are 
clindamycin, broad-spectrum penicillins, 
cephalosporins, and in several case reports, 
quinolones.8,9 
Methotrexate or paclitaxel chemotherapy can 
also present risks.8 
Several case reports have identified C. difficile 
colitis associated with “triple” regimen therapy to 
eradicate Helicobacter pylori.  The regimens 
consisted of clarithromycin, metronidazole, and 
omeprazole or clarithromycin, amoxicillin, and 
lansoprazole.10-12 
Proton pump inhibitors are prescribed for a 
variety of indications including duodenal and 
gastric ulcer, esophagitis, gastroesophageal reflux 
disease, peptic ulcer disease, Zollinger-Ellison 
Syndrome, heartburn, prophylaxis of upper 
gastrointestinal bleeding associated with non-
steroidal anti-inflammatory agent use, and acute 
upper gastrointestinal bleeding.  The overuse of 
acid-suppressing drugs has been described in 
hospitalized patients.13  Inappropriate use 
especially as prophylaxis of stress ulcers in low-
risk patients is common.13   
The normal pH of the stomach is a host 
defense and barrier to ingested pathogens.14  
Bacterial overgrowth and colonization with fecal 
bacteria have been identified in studies with acid-
inhibitory therapy.14,15  Acid-suppressing drugs are 
associated with bacterial overgrowth in the 
stomach and influenza viruses in the gastric 
mucosa.14,16  Studies have also shown that 
bacterial overgrowth depends on the intensity of 
inhibition of gastric acid secretion and 
corresponding increase in pH.  Proton pump 
inhibitors have greater inhibition of gastric acid 
secretion compared with H2 receptor 
antagonists.15,17   
Careful consideration should be taken when 
proton pump inhibitors are prescribed for 
inpatients when concomitant antibiotics are used.  
Prophylactic use of proton pump inhibitors should 
be examined for appropriateness given the 
findings of this study.  Accepted indications for 
proton pump inhibitors include treatment of active 
gastroesophageal reflux disease (GERD), acute 
upper gastrointestinal bleeding, active peptic ulcer 
disease, and Zollinger-Ellison Syndrome.18,19  
Preliminary evidence suggests that development 
of C. difficile infection is a potential consequence 
when proton pump inhibitors are combined with 
antibiotic therapy in hospitalized patients
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[Evidence level B, clinical cohort study, case-
control study].4 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
 
Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based 
clinical review article.  Am Fam Physician 2002;65:251-8. 
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